Travere Therapeutics Inc. (NASDAQ: TVTX) received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application No. 19/253,088, which covers certain methods of using FILSPARI (sparsentan) in IgA nephropathy treatment.

The patent application, titled "Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders," is expected to provide U.S. patent coverage for specific methods of using sparsentan in IgA nephropathy until October 2037, according to the company's statement.

The application will become a U.S. patent following payment of the issue fee and standard USPTO post-allowance processing. Travere plans to submit the issued patent for listing in the FDA's Orange Book after it is granted.

FILSPARI is currently indicated to slow kidney function decline in adults with primary IgA nephropathy who are at risk for disease progression, and to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis without nephrotic syndrome.

The drug is available only through a restricted program called the FILSPARI REMS due to hepatotoxicity risks. The medication carries a boxed warning for hepatotoxicity and embryo-fetal toxicity.